Monte Rosa Therapeutics Stock Quote GLUE - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

5.61

Bid

5.29

Ask

8.91

Volume

0.00 Day's Range 0.00

2.44 52 Week Range 8.84

Market Cap

281.364M

Previous Close

5.61

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

138,138

Shares Outstanding

50,154,073

Dividend Yield

PE Ratio

-2.08

Earnings Per Share (EPS)

-2.7

Revenue

Net Profit

-135.35M

Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.monterosatx.com.

Headquarters

Wilmington, Delaware, USA

Founded

1970

Monte Rosa Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GLUE. The last closing price for Monte Rosa Therapeutics was $5.61. Over the last year, Monte Rosa Therapeutics shares have traded in a share price range of $ 2.44 to $ 8.84.

Monte Rosa Therapeutics currently has 50,154,073 shares outstanding. The market capitalization of Monte Rosa Therapeutics is $281.36 million. Monte Rosa Therapeutics has a price to earnings ratio (PE ratio) of -2.08.

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2...

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.04	0.718132854578	5.57	6.045	5.11	93881	5.47622558	CS
4	-1.29	-18.6956521739	6.9	8.22	5.11	122093	6.4851269	CS
12	0.81	16.875	4.8	8.84	4.185	138138	6.31258456	CS
26	2.83	101.798561151	2.78	8.84	2.765	181941	5.18947455	CS
52	0.99	21.4285714286	4.62	8.84	2.44	196643	5.3732403	CS
156	-16.39	-74.5	22	45.56	2.44	207434	11.321127	CS
260	-16.39	-74.5	22	45.56	2.44	207434	11.321127	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CYCCCyclacel Pharmaceuticals Inc	$ 2.34 (72.06%)	699.57k
WGSGeneDx Holdings Corporation	$ 15.10 (37.27%)	73.01k
GWAVGreenwave Technology Solutions Inc	$ 0.0865 (33.08%)	13.1M
MRINMarin Software Incorporated	$ 3.24 (24.14%)	159.72k
WRNTWarrantee Inc	$ 0.33 (22.22%)	3.47k
LICNLichen China Limited	$ 1.53 (-24.63%)	138.34k
ICLKiClick Interactive Asia Group Ltd	$ 1.00 (-15.25%)	330
SGBXSafe and Green Holdings Corporation	$ 0.12 (-14.89%)	1.41k
CSLRComplete Solaria Inc	$ 0.6289 (-13.87%)	68.89k
BSGMBioSig Technologies Inc	$ 1.16 (-13.43%)	2.08k
GWAVGreenwave Technology Solutions Inc	$ 0.0865 (33.08%)	13.1M
FFIEFaraday Future Intelligent Electric Inc	$ 0.0432 (3.35%)	1.85M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	$ 8.87 (-5.24%)	1.27M
JAGXJaguar Health Inc	$ 0.2223 (6.88%)	950.4k
TSLATesla Inc	$ 189.16 (-2.52%)	813.06k